JUPITER, FL, April 29, 2014 – Resveratrol has been much in the news as the component of grapes and red wine associated with reducing “bad cholesterol,” heart disease and some types of cancer. Also found in blueberries, cranberries, mulberries, peanuts and pistachios, resveratrol is associated with beneficial health effects in aging, inflammation and metabolism.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have now identified one of the molecular pathways that resveratrol uses to achieve its beneficial action. They found that resveratrol controls the body’s inflammatory response as a binding partner with the estrogen receptor without stimulating estrogenic cell proliferation, which is good news for its possible use as a model for drug design.
The study was recently published as an accepted manuscript in the online journal eLife, a publication supported by the Howard Hughes Medical Institute, the Max Planck Society and the Wellcome Trust.
“Estrogen has beneficial effects on conditions like diabetes and obesity but may increase cancer risk,” said Kendall Nettles, a TSRI associate professor who led the study. “What hasn’t been well understood until now is that you can achieve those same beneficial effects with something like resveratrol.”
The problem with resveratrol, Nettles said, is that it really doesn’t work very efficiently in the body. “Now that we understand that we can do this through the estrogen receptor, there might compounds other than resveratrol out there that can do the same thing—only better,” he said.
“Our findings should lead scientists to reconsider the estrogen receptor as a main target of resveratrol—and any analogues,” said Jerome C. Nwachukwu, the first author of the study and a research associates in the Nettles laboratory. “It has gotten swept under the rug.”
In the new study, Nettles, Nwachukwu and their colleagues found that resveratrol is an effective inhibitor of interleukin 6 (IL-6), a pro-inflammatory protein that is part of the immune system (although IL-6 can be anti-inflammatory during exercise). High levels of IL-6 are also associated with poor breast cancer patient survival. According to the study, resveratrol regulates IL-6 without stimulating cell proliferation by altering a number of co-regulators of the estrogen receptor.
In addition to Nwachukwu and Nettles, other authors of the study, “Resveratrol Modulates the Inflammatory Response via An Estrogen Receptor-Signal Integration Network,” include Sathish Srinivasan, Nelson E. Bruno , Travis S. Hughes, Julie A. Pollock, Olsi Gjyshi, Valerie Cavett, Jason Nowak, Ruben D. Garcia-Ordonez , Patrick R. Griffin, Douglas J. Kojetin and Michael D. Conkright of TSRI; Alex A. Parent and John A. Katzenellenbogen of the University of Illinois; and René Houtman of PamGene International, The Netherlands. For more information, see http://elifesciences.org/content/early/2014/04/24/eLife.02057
The study was supported by the National Institutes of Health (grants PHS 5R37DK015556; 5R33CA132022, 5R01DK077085, 1U01GM102148, R01DK101871 and F32DK097890), the BallenIsles Men’s Golf Association, the Frenchman’s Creek Women for Cancer Research, the State of Florida and the James and Esther King Biomedical Research Program, Florida Department of Health (1KN-09).
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.
# # #
Office of Communications